RxDoctor Payments Data

Mechery Davis, MD

Internal Medicine · Warwick, RINPI 1407824477

Payments from drug & device makers

$1,504in general payments, 2019–2025

Across 73 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$239
  • Phathom Pharmaceuticals, Inc.$233
  • Pfizer$203
  • AstraZeneca$139
  • Abbott$131
  • Amarin Pharma, Inc.$128
  • plus $432 from 10 others

What the payments were for

  • Food & beverage$1,36991%
  • Education$1359%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,504 in reported general payments places this provider in the 85th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$68,026
Medicare patients
122
Services billed
653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$90,076
Wellbutrin XlBupropion Hcl24$55,898
JardianceEmpagliflozin55$39,674
EliquisApixaban57$37,689
XareltoRivaroxaban48$33,619
Diclofenac Potassium11$32,573
CreonLipase/Protease/Amylase20$26,437
RybelsusSemaglutide16$25,733
JanuviaSitagliptin Phosphate25$22,940
OxycontinOxycodone Hcl37$19,718
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,186
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate43$10,610
Spiriva RespimatTiotropium Bromide11$10,526
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$8,893
Atorvastatin Calcium608$7,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$112$50,20066 claims
PfizerEliquis$203$37,68957 claims
Johnson & JohnsonXarelto$239$33,61948 claims
AbbVieCreon$18$26,43720 claims
MerckJanuvia, Janumet$35$26,17437 claims
GSKTrelegy Ellipta, Breo Ellipta$49$21,15836 claims
AstraZenecaBreztri Aerosphere, Symbicort$139$14,30733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →